SOHO State of the Art Updates and Next Questions | Current Status and Future Directions of Donor Selection
Clinical Lymphoma Myeloma and Leukemia · 2024
DOI: 10.1016/j.clml.2024.05.011 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Rohtesh S Mehta. Beteiligte Einrichtung: Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA. Electronic address: rmehta@fredhutch.org. Hauptthemen laut MEDLINE: Donor Selection, Hematopoietic Stem Cell Transplantation, Histocompatibility Testing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
The landscape of HLA matching in hematopoietic cell transplantation (HCT) is continuously advancing, introducing more nuanced criteria beyond traditional 10/10 HLA-A, -B, -C, and -DRB1 allele matching. For 10/10 matched donors, prioritizing a donor with a "core" permissive HLA-DPB1 mismatch is recommended over "noncore" permissive mismatches, with nonpermissive mismatches being the least prefered. In the one-antigen mismatched setting (7/8 HLA-matched), HLA-C matching, particularly avoiding high-expression mismatches at residues 116 or 77/80, is preferred over HLA-A or HLA-B mismatches. HLA B-leader matching is beneficial in both one-antigen mismatched and haploidentical HCT. Additionally, specific HLA mismatches in haploidentical HCT, such as DRB1 mismatches with DQB1 matches and DPB1 nonpermissive mismatches are linked to better outcomes. Among non-HLA factors, evidence consistently underscores the pivotal impact of donor age on overall survival. For HLA-mismatched transplants, including haploidentical HCT, avoidance of donors against whom the recipient has preformed donor-specific antibodies is paramount. Selecting a cytomegalovirus (CMV) seronegative donor is important particularly for CMV-negative recipients; however, more research is needed in the letermovir prophylaxis era. The impact of ABO-matching on transplant outcomes is debatable. Other unanswered questions include defining "younger" donors and establishing hierarchy in donor selection based on factors like CMV status, ABO compatibility, or sex-mismatch, to name a few. Future research addressing these issues will refine donor selection algorithms and improve transplant success. In conclusion, selecting a donor for HCT requires multifaceted considerations, integrating evolving HLA-matching criteria and non-HLA factors, to optimize HCT outcomes in this rapidly advancing field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA. Electronic address: rmehta@fredhutch.org.
Zitieren
APA
Mehta, R. S. (2024). SOHO State of the Art Updates and Next Questions | Current Status and Future Directions of Donor Selection. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.05.011
Vancouver
Mehta RS. SOHO State of the Art Updates and Next Questions | Current Status and Future Directions of Donor Selection. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.05.011
BibTeX
@article{Mehta2024,
author = {Mehta, Rohtesh S},
title = {SOHO State of the Art Updates and Next Questions | Current Status and Future Directions of Donor Selection},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
doi = {10.1016/j.clml.2024.05.011}
}
EUVIMED